XOMA Corporation (XOMA) |
20.55 -0.3 (-1.44%)
|
02-03 13:54 |
Open: |
20.525 |
Pre. Close: |
20.85 |
High:
|
21.06 |
Low:
|
20.3545 |
Volume:
|
52,065 |
Market Cap:
|
235(M) |
|
|
Technical analysis |
as of: 2023-02-03 2:21:23 PM |
Overall:
|
|
Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
Target: |
Six months: 24.84 One year: 27.45  |
Support: |
Support1: 17.64 Support2: 14.68  |
Resistance: |
Resistance1: 21.27 Resistance2: 23.51  |
Pivot: |
21.57  |
Moving Average: |
MA(5): 20.65 MA(20): 21.24 
MA(100): 18.72 MA(250): 20.49  |
MACD: |
MACD(12,26): 0.2 Signal(9): 0.5  |
Stochastic oscillator: |
%K(14,3): 28.4 %D(3): 33.5  |
RSI: |
RSI(14): 49.4  |
52-week: |
High: 32.09 Low: 15.68 |
Average Vol(K): |
3-Month: 25 (K) 10-Days: 25 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ XOMA ] has closed above bottom band by 21.3%. Bollinger Bands are 19.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
20.91 - 20.99 |
20.99 - 21.07 |
Low:
|
19.97 - 20.06 |
20.06 - 20.15 |
Close:
|
20.7 - 20.85 |
20.85 - 20.99 |
|
Company Description |
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. |
Headline News |
Thu, 02 Feb 2023 Congenital Hyperinsulinism Market: Analysis of Epidemiology ... - Digital Journal
Tue, 31 Jan 2023 Botulism Pipeline Report provides an analysis of 4+ key companies ... - Digital Journal
Tue, 24 Jan 2023 Amolyt Pharma inks research and option deal with XOMA - The Pharma Letter
Thu, 12 Jan 2023 Should You Sell XOMA Corp (XOMA) in Biotechnology Industry? - InvestorsObserver
Fri, 06 Jan 2023 XOMA Announces New Employment Inducement Grants Under ... - GlobeNewswire
Tue, 22 Nov 2022 XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon - Yahoo Finance
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. |
11 (M) |
Shares Float |
8 (M) |
% Held by Insiders
|
0.6 (%) |
% Held by Institutions
|
59.5 (%) |
Shares Short
|
356 (K) |
Shares Short P.Month
|
382 (K) |
Stock Financials |
EPS
|
0.77 |
EPS Est Next Qtl
|
-0.19 |
EPS Est This Year
|
-2.94 |
EPS Est Next Year
|
-1.33 |
Book Value (p.s.)
|
7.69 |
Profit Margin (%)
|
45 |
Operating Margin (%)
|
49.2 |
Return on Assets (ttm)
|
8.6 |
Return on Equity (ttm)
|
14.6 |
Qtrly Rev. Growth
|
9.1 |
Gross Profit (p.s.)
|
3.35 |
Sales Per Share
|
3.62 |
EBITDA (p.s.)
|
1.78 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
22 (M) |
Levered Free Cash Flow
|
9 (M) |
Stock Valuations |
PE Ratio
|
26.34 |
PEG Ratio
|
-0.8 |
Price to Book value
|
2.67 |
Price to Sales
|
5.67 |
Price to Cash Flow
|
10.45 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
2016-10-17 |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|